Related Experiment Video
Updated: Dec 11, 2025
05:50
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
Published on: September 26, 2025
1.0K
Establishment and validation of a drug-target microarray for SARS-CoV-2
Peng Chen1, Zehua Zeng2, Hongwu Du2
1Beijing Key Laboratory of Traditional Chinese Medicine Basic Research on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing, China.
Biochemical and Biophysical Research Communications
|August 24, 2020
Summary
This study developed a COVID-19 protein microarray to identify therapeutic targets for SARS-CoV-2. This tool aids in screening natural products for drug discovery, advancing molecular pharmacology research.
Area of Science:
- Pharmacology
- Virology
- Drug Discovery
Background:
- The COVID-19 pandemic has highlighted the need for effective treatments.
- While herbal medicines show clinical value, their molecular mechanisms against SARS-CoV-2 remain unclear.
- Understanding host and viral targets is crucial for developing novel therapies.
Purpose of the Study:
- To construct a COVID-19 protein microarray for identifying therapeutic targets.
- To facilitate the screening of natural products for potential antiviral and anti-inflammatory agents.
- To provide a tool for studying the molecular pharmacology of natural products in the context of COVID-19.
Main Methods:
- Development of a protein microarray containing key SARS-CoV-2 targets.
- Inclusion of host cellular targets involved in antiviral and anti-inflammatory responses.
- Implementation of rigorous quality control measures for microarray validation.
Main Results:
- The constructed microarray successfully passed quality control tests.
- The microarray is suitable for drug target screening of bioactive natural products.
- It offers a valuable platform for investigating natural product pharmacology.
Conclusions:
- The COVID-19 protein microarray is a validated tool for drug target screening.
- This platform will accelerate the discovery of natural product-based therapies for COVID-19.
- It supports research into the molecular pharmacology of natural products against SARS-CoV-2.
